Will Oscar Health achieve FY2026 operating income at or above $250M (low end of guidance)?

The $750M swing from FY2025's operating loss to the low end of guidance is extraordinarily ambitious. Four lenses converge on risk adjustment as the dominant threat — each 100 bps of unexpected increase costs $190M. Management has a documented pattern of over-projecting profitability (FY2025 was supposed to be profitable, delivered $443M net loss). The 450 bps MLR improvement required is possible with the 28% rate increase but assumes risk adjustment stability AND member retention AND no adverse morbidity surprises. The wide guidance range ($250-450M, a $200M spread) itself signals management's low confidence. Historical base rate for this magnitude of profitability swing in one year is low.

The math works on paper: $19B revenue x 82.9% MLR (midpoint guide) = $15.75B medical costs, $19B x 16.05% SG&A = $3.05B admin, leaving ~$200M operating income before risk adjustment. But this assumes the MLR guide is accurate and risk adjustment doesn't surprise. The 28% rate increase provides genuine pricing headroom. SG&A improvement trajectory (160 bps in FY2025) is credible. The key variable is whether risk adjustment stays at ~20% — if it goes to 21%+, the profit is wiped out. Given the structural uncertainty around risk adjustment and management's track record, probability is below 40%.

I apply a significant credibility discount given the committee's 3-lens convergence on management over-promising. FY2025 was supposed to be the profitability year — it produced a $443M loss. The CEO/CFO tone divergence (CEO 'stronger than ever' vs CFO 'most difficult thing we have to do') suggests internal awareness of high execution risk. The subsidy cliff introduces a revenue risk that could compound with risk adjustment risk. If both go wrong simultaneously (higher churn AND higher risk adjustment), the loss could actually worsen from FY2025. Probability below 35%.

The 28% rate increase and 61% revenue growth create genuine tailwinds. SG&A leverage is proven (160 bps improvement). The question is binary — $250M threshold, not the midpoint. ACA industry dynamics may have normalized after the 2025 morbidity shock. Oscar's proactive pricing for subsidy expiration suggests learning from past mistakes. Still below 50% due to risk adjustment uncertainty and management track record, but this is closer to achievable than the market's skepticism implies.

The combination of risk factors is daunting: risk adjustment could take $190M+ if it surprises by 100 bps, the subsidy cliff could reduce the revenue base, and the bronze-heavy mix introduces new cost dynamics. Even the low end ($250M) requires everything to go right — MLR improvement, risk adjustment stability, member retention, and continued SG&A gains. History says everything rarely goes right simultaneously for a company with this complexity of risk. Below 40%.

I'm genuinely uncertain here. The rate increase is substantial and the FY2025 industry reset may have cleaned up the morbidity issue. Oscar's pricing explicitly assumed subsidy expiration, which is the most conservative planning assumption. If the market contraction is at the low end (5-20%), Oscar's revenue base holds better than feared. The company's AI-driven SG&A improvements are real. But risk adjustment remains the wild card that could erase hundreds of millions. Low confidence, slight lean NO.

Management guided $250-450M after missing by $443M in FY2025. The turnaround requires a $750M swing. Rate increases help but risk adjustment is the wild card. Management credibility is low. Lean NO at ~38%.

The 28% rate increase is meaningful and the industry had a reset year. If morbidity normalizes in 2026, the rate increase provides significant margin expansion. The question asks about $250M, the low end. ACA carriers broadly are expected to improve in 2026. Closer to coin-flip than my initial assessment, but still lean NO due to execution risk.

The committee's HIGHER_SCRUTINY posture and 4-lens convergence on risk adjustment as the central threat suggest the probability of hitting $250M is below 50%. The management credibility gap adds to the discount. Rate increases provide tailwind but may not overcome structural challenges. Lean NO.